ReviewImmunity, inflammation and disease2023
COVID-19 as a trigger of Guillain-Barré syndrome: A review of the molecular mechanism.
Review in Immunity, inflammation and disease, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 1 synthesis or guideline pooled it, 32 citations in OpenAlex.
- Possible temporal relationship between SARS-CoV-2 infection and anti-NMDA receptor encephalitis: a meta-analysis.Translational psychiatry · 2024Pooled it
- Serum inflammatory and coagulation markers in GBS infection and adverse pregnancy outcomes.Biomarkers in medicine · 2026Article
- Clinical and Electrophysiological Characteristics of Guillain-Barré Syndrome Across Pre-Pandemic, Pandemic, and Post-Pandemic Periods: A Ten-Year Retrospective Cohort Study.Noro psikiyatri arsivi · 2026Article
- Nephrotic syndrome and Guillain-Barré syndrome following umbilical cord blood transplantation in acute myeloid leukemia: correlated with COVID-19?BMC infectious diseases · 2025Article
- Impact of COVID-19 vaccination coverage on global disability burden of Guillain-Barré syndrome.NPJ vaccines · 2025Article
- Association Between Thyroid Hormone Levels and Disease Prognosis in Guillain-Barré Syndrome: A Retrospective Study.Health science reports · 2025Article
- Neuropilin-1 as a Neuroinflammatory Entry Factor for SARS-CoV-2 Is Attenuated in Vaccinated COVID-19 Patients: A Case-Control Study.Health science reports · 2025Article
- Article
- Mechanistic Insights into Drug-Induced Guillain-Barré Syndrome: A Large-Cohort Analysis of the FAERS Database.Pharmaceuticals (Basel, Switzerland) · 2025Article
- Identifying potential co-expressed genes and molecular mechanisms linking post-COVID-19 and Guillain-Barre syndrome through neutrophil extracellular trap-related genes.Frontiers in neurology · 2025Article
- Impact of COVID-19 on Guillain Barre Syndrome (GBS) insights from an Iranian referral center.Frontiers in neurology · 2025Article
- Analysis of Nirmatrelvir Entry into Pulmonary Lining Fluid in Patients with COVID-19: A Unique Perspective to Explore and Understand the Target Plasma Concentration of 292 ng/mL in Antiviral Activity.Immunity, inflammation and disease · 2024Article
- Demyelination in Patients with POST-COVID Depression.Journal of clinical medicine · 2024Article
- Relative frequencies and clinical features of Guillain-Barré Syndrome before and during the COVID-19 pandemic in North China.BMC infectious diseases · 2024Article
- Guillain-Barré Syndrome After a SARS-CoV-2 Vaccine.Cureus · 2024Article
- Case report: Rare Guillain-Barré syndrome variants and mild encephalitis/encephalopathy with a reversible splenial lesion as the para-infectious manifestations of SARS-CoV-2 infection.Frontiers in immunology · 2024Article
- Long COVID, the Brain, Nerves, and Cognitive Function.Neurology international · 2023Review
- COVID-19 as a trigger of Guillain-Barré syndrome: A review of the molecular mechanism.Immunity, inflammation and disease · 2023Review
- Decreased Incidence of Guillain-Barré Syndrome during the COVID-19 Pandemic: A Retrospective Population-Based Study.Neuroepidemiology · 2023Article
- Molecular and Cellular Mechanisms Underlying Neurological and Neuropsychological Manifestations of COVID-19.Innovations in clinical neuroscienceReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) caused a pandemic with serious complications. After coronavirus disease 2019 (COVID-19), several post-acute COVID-19 syndromes (PACSs) and long-COVID sequels were reported. PACSs involve many organs, including the nervous, gustatory, and immune systems. One of the PACSs after SARS-CoV-2 infection and vaccination is Guillain-Barré syndrome (GBS). The incidence rate of GBS after SARS-CoV-2 infection or vaccination is low. However, the high prevalence of COVID-19 and severe complications of GBS, for example, autonomic dysfunction and respiratory failure, highlight the importance of post-COVID-19 GBS. It is while patients with simultaneous COVID-19 and GBS seem to have higher admission rates to the intensive care unit, and demyelination is more aggressive in post-COVID-19 GBS patients. SARS-CoV-2 can trigger GBS via several pathways like direct neurotropism and neurovirulence, microvascular dysfunction and oxidative stress, immune system disruption, molecular mimicry, and autoantibody production. Although there are few molecular studies on the molecular and cellular mechanisms of GBS occurrence after SARS-CoV-2 infection and vaccination, we aimed to discuss the possible pathomechanism of post-COVID-19 GBS by gathering the most recent molecular evidence.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.